Axon posted a disasterous loss of U.S$10m last calendar year.
Its shareholder update of December 2002 said they would inititate R&D constraints and shed some staff to save U.S$4M in this calender year.
Well, by simple arithmetic, Axon was still staring at a U.S$6m deficit.
The only way that they could be running at breakeven, as disclosed in their response to the stock exchange today, is if they have posted a pretty impressive growth in sales.
Break even is boring, but growth, especially at this low market cap, is attractive.
- Forums
- ASX - By Stock
- growth stock
growth stock
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online